In addition to its diagnostic properties, in vivo studies with xenografted mouse, showed that the treatment with a silencer oligonucleotide of miR-429 is able to cause a delay of tumor proliferation, thus making miR-429 a possible candidate molecule for the development of new therapeutic tools in HER2+ BC. This evidence concerns the gene ERBB2 and breast cancer.